Accellix Inc. and Streck collaborate to advance cell therapy with quality control

Accellix™, a pioneer in automated flow cytometry, and Streck, a recognized leader in quality control materials for flow cytometry, hematology and molecular diagnostics, have announced a strategic collaboration with the addition of the Accellix Automated Cell Phenotyping Platform to Streck’s CD-Chex Plus® (RUO) control.

The Accellix platform is a compact, fully automated flow cytometer designed for point-of-need environments. It uses single-use, microfluidic cartridges to automate the entire cell phenotyping process, from antibody staining to flow cytometry acquisition and data analysis. This enables rapid, reproducible results without the need for complex instrumentation or specialized operators.

By integrating CD-Chex Plus (RUO) control into the Accellix workflow, users can assess the Accellix platform performance and ensure reliable operation. This addition supports routine monitoring and helps users maintain trust in their data without introducing complexity or requiring a separate or centralized lab infrastructure.

“This collaboration reflects our commitment to helping cell therapy developers and labs worldwide achieve faster, more reliable results. By aligning with Streck and CD-Chex Plus (RUO) control, we’re making it easier to simplify flow cytometry quality control across a multitude of instruments, locations and environments utilizing the Accellix technology,” said Rey Mali, Chief Operations Officer at Accellix.

“We’re excited to work with a team that shares our mission to support laboratories and companies with reliable, streamlined solutions that enable positive outcomes in health care,” said Matt Thummel, Director of Business Segment – Hematology, Body Fluids and Flow Cytometry at Streck.

CD-Chex Plus (RUO) is For Research Use Only. Not for use in diagnostic procedures.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>